mpeg5kda-b-[(doxo-hydglu)6-r-leu10]

**mPEG5kDa-b-[(Doxo-hydGlu)6-r-Leu10]** is a synthetic polymer-drug conjugate designed for enhanced drug delivery. The construct consists of a methoxy polyethylene glycol (mPEG) block with a molecular weight of 5 kDa, attached to a block copolymer structure. The second block is a polypeptide made of repeating units of doxorubicin (Doxo) conjugated via a hydrazone-linked glutamic acid (hydGlu), repeated six times, and leucine (Leu), repeated ten times. The mPEG component serves to enhance the solubility, bioavailability, and circulation time of the drug, as well as reduce immunogenicity and systemic toxicity[1]. The hydrazone linker between doxorubicin and glutamic acid is designed to be acid-sensitive, enabling controlled drug release in acidic environments such as the tumor microenvironment[2]. The leucine-rich block may contribute to self-assembly into nanoparticles or micelles, further improving tumor targeting and retention. **Mechanism of Action:** The active drug, doxorubicin, intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cancer cells. The mPEG block and polypeptide architecture aim to optimize pharmacokinetics, reduce side effects, and enhance tumor accumulation through the enhanced permeability and retention (EPR) effect. **Primary Indication:** While not specifically mentioned in the provided sources, similar constructs are typically developed for oncology indications, particularly solid tumors where controlled drug release and tumor targeting are advantageous.